Loading...
•
Sep 30, 2022
BioCryst Q3 2022 Earnings Report
BioCryst reported Q3 2022 financial results with ORLADEYO net revenue of $66.0 million and an increase in total revenues to $75.8 million.
Key Takeaways
BioCryst Pharmaceuticals reported strong Q3 2022 financial results, driven by ORLADEYO's net revenue of $66.0 million. Total revenues increased to $75.8 million, and the company is on track to more than double ORLADEYO sales in 2022 compared to 2021.
ORLADEYO Q3 2022 net revenue reached $66.0 million, positioning the company to more than double sales in 2022 compared to 2021.
Underlying patient trends remained strong, with a nine percent growth in paid patients during Q3 2022.
The company expanded its complement pipeline by advancing BCX10013 into clinical development and adding discovery targets.
BCX9930 patient screening is underway, with data expected from approximately 15 newly-enrolled patients in mid-2023.
Forward Guidance
BioCryst expects full year 2022 net ORLADEYO revenue to be $255 million and operating expenses, not including non-cash stock compensation, to be between $365 million and $370 million.
Positive Outlook
- Full year 2022 net ORLADEYO revenue to be $255 million.
- The company expects to bring rare disease patients many more oral therapies.
- The company continued to see strong underlying growth fundamentals from patients and physicians in the third quarter.
- The company expects to see further growth dynamics in the fourth quarter.
- The company is on track to more than double ORLADEYO revenue in 2022 compared to 2021.
Challenges Ahead
- The ongoing COVID-19 pandemic could create challenges in all aspects of BioCryst’s business.
- BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize ORLADEYO, could take longer or be more expensive than planned.
- The results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...